Who
Glenn Pierce
Director
Company insider
Files Form 4 as: Interim CSO, Voyager Therapeutics; Director, Global Blood Therapeutics.
In numbers
- Trades disclosed
- 47
- Buys
- 1
- Sells
- 1
- Bought
- $92K
- Sold
- $64K
- Companies
- 2
- Companies where not an officer
- 1
- First trade
- 8 Feb 2016
- Last trade
- 9 Jun 2026
- Last filed
- 11 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 9 Jun 2026filed 11 Jun 2026 | VYGR Voyager Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 9 Jun 2026filed 11 Jun 2026 | VYGR Voyager Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 3 Jun 2025filed 4 Jun 2025 | VYGR Voyager Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —24,000 at $0.00 | filing |
| 5 Jun 2024filed 7 Jun 2024 | VYGR Voyager Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —24,000 at $0.00 | filing |
| 6 Jun 2023filed 7 Jun 2023 | VYGR Voyager Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —22,000 at $0.00 | filing |
| 5 Oct 2022filed 6 Oct 2022 | Global Blood Therapeuticsoption or derivative | SEC FORM 4 Code D | —3,600 | filing |
| 5 Oct 2022filed 6 Oct 2022 | Global Blood Therapeuticsoption or derivative | SEC FORM 4 Code D | —15,000 | filing |
| 5 Oct 2022filed 6 Oct 2022 | Global Blood Therapeuticsoption or derivative | SEC FORM 4 Code D | —15,000 | filing |
| 5 Oct 2022filed 6 Oct 2022 | Global Blood Therapeuticsoption or derivative | SEC FORM 4 Code D | —15,000 | filing |
| 5 Oct 2022filed 6 Oct 2022 | Global Blood Therapeuticsoption or derivative | SEC FORM 4 Code D | —15,000 | filing |
| 5 Oct 2022filed 6 Oct 2022 | Global Blood Therapeuticsoption or derivative | SEC FORM 4 Code D | —7,500 | filing |
| 5 Oct 2022filed 6 Oct 2022 | Global Blood Therapeuticsoption or derivative | SEC FORM 4 Code D | —5,247 | filing |
| 5 Oct 2022filed 6 Oct 2022 | Global Blood Therapeuticsoption or derivative | SEC FORM 4 Code D | —5,600 | filing |
| 5 Oct 2022filed 6 Oct 2022 | Global Blood Therapeuticsoption or derivative | SEC FORM 4 Code D | —5,600 | filing |
| 5 Oct 2022filed 6 Oct 2022 | Global Blood Therapeutics | SEC FORM 4 Code D | —26,437 | filing |
| 14 Jul 2022filed 18 Jul 2022 | VYGR Voyager TherapeuticsBiotechnology | SEC FORM 4 Sold | $64K9,512 at $6.70 | filing |
| 14 Jun 2022filed 16 Jun 2022 | Global Blood Therapeuticsoption or derivative | SEC FORM 4 Code M | —3,600 at $0.00 | filing |
| 14 Jun 2022filed 16 Jun 2022 | Global Blood Therapeuticsoption or derivative | SEC FORM 4 Code A | —5,600 at $0.00 | filing |
| 14 Jun 2022filed 16 Jun 2022 | Global Blood Therapeuticsoption or derivative | SEC FORM 4 Code A | —3,600 at $0.00 | filing |
| 14 Jun 2022filed 16 Jun 2022 | Global Blood Therapeutics | SEC FORM 4 Code M | —3,600 | filing |
News
No headline names them, or the companies they trade most, lately.